Esq JD - Iovance Biotherapeutics President, CEO
| IOVA Stock | USD 8.55 0.31 3.76% |
Insider
Esq JD is President, CEO of Iovance Biotherapeutics
| Age | 48 |
| Address | 825 Industrial Road, San Carlos, CA, United States, 94070 |
| Phone | 650 260 7120 |
| Web | https://www.iovance.com |
Iovance Biotherapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2916) % which means that it has lost $0.2916 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5665) %, meaning that it created substantial loss on money invested by shareholders. Iovance Biotherapeutics' management efficiency ratios could be used to measure how well Iovance Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 24, 2024, Return On Tangible Assets is expected to decline to -0.85. In addition to that, Return On Capital Employed is expected to decline to -0.72. At present, Iovance Biotherapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 496.1 M, whereas Total Current Assets are forecasted to decline to about 218.7 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Nur Nicholson | Apellis Pharmaceuticals | 54 | |
| David Glynn | Krystal Biotech | N/A | |
| Alex Kane | PTC Therapeutics | N/A | |
| Daren Ure | Hepion Pharmaceuticals | N/A | |
| Eric Pauwels | PTC Therapeutics | 63 | |
| Louise RodinoKlapac | Sarepta Therapeutics | 46 | |
| FACS FACS | PTC Therapeutics | 50 | |
| Cedric MD | Apellis Pharmaceuticals | 52 | |
| Malte Greune | CureVac NV | 59 | |
| BSc BSc | Hepion Pharmaceuticals | 66 | |
| Gloria Lin | Krystal Biotech | N/A | |
| Ryan Brown | Sarepta Therapeutics | 46 | |
| Antony Blanc | CureVac NV | 54 | |
| MBA JD | Apellis Pharmaceuticals | 51 | |
| Igor MSc | CureVac NV | 55 | |
| Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
| Ellen Welch | PTC Therapeutics | N/A | |
| Katherine Tuminello | Krystal Biotech | N/A | |
| Todd MD | Hepion Pharmaceuticals | 55 | |
| William Ciambrone | Sarepta Therapeutics | 60 | |
| Thorsten Schuller | CureVac NV | N/A | |
Management Performance
| Return On Equity | -0.57 | ||||
| Return On Asset | -0.29 |
Iovance Biotherapeutics Leadership Team
Elected by the shareholders, the Iovance Biotherapeutics' board of directors comprises two types of representatives: Iovance Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Iovance. The board's role is to monitor Iovance Biotherapeutics' management team and ensure that shareholders' interests are well served. Iovance Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Iovance Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Esq JD, President, CEO | ||
| Igor Bilinsky, Chief Officer | ||
| Friedrich MD, Chief Officer | ||
| Howard MBA, Chief Officer | ||
| Kevin Smyth, Executive Quality | ||
| JeanMarc MBA, Chief Officer | ||
| Sara Pellegrino, Vice Relations | ||
| Madan Jagasia, Ex Affairs | ||
| Tracy Winton, Executive Resources | ||
| Brian MBA, Senior Technology | ||
| James MBA, Executive Commercial |
Iovance Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Iovance Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.57 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (1.52) % | ||||
| Current Valuation | 2.29 B | ||||
| Shares Outstanding | 304.78 M | ||||
| Shares Owned By Insiders | 0.52 % | ||||
| Shares Owned By Institutions | 87.93 % | ||||
| Number Of Shares Shorted | 59.73 M | ||||
| Price To Earning | (3.51) X | ||||
| Price To Book | 3.37 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Iovance Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Iovance Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Iovance Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Iovance Biotherapeutics Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iovance Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. If investors know Iovance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iovance Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 0.327 | Quarterly Revenue Growth 123.851 | Return On Assets (0.29) | Return On Equity (0.57) |
The market value of Iovance Biotherapeutics is measured differently than its book value, which is the value of Iovance that is recorded on the company's balance sheet. Investors also form their own opinion of Iovance Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iovance Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iovance Biotherapeutics' market value can be influenced by many factors that don't directly affect Iovance Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iovance Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.